group reported an elegantly designed randomized, double-blind, placebo controlled study of GSK2618960 to investigate pharmacokinetics, safety, and tolerability as well as pharmacodynamics. The latter was performed by a target engagement assay as illustrated by receptor occupancy of the interleukin-7 receptor after single administration of the compound. In the T-lymphocytes of the PBMCs already with the lowest dose, a complete receptor occupancy was observed for 7 consecutive days while the higher dose showed 21-day full occupancy of the IL-7Ra. The functional evaluation of the compound was performed by investigating the phosphorylation status of IL-7R downstream inhibition of STAT5 upon ex vivo IL-7 exposure of PBMCs. The authors showed that the highest dose lead to full STAT5 inhibition. In addition, the PK-PD relationship was established showing a target concentration of 2 μg/ml necessary to obtain full receptor occupancy. With these PK-PD results, it was then possible to take rational steps into proof-of-concept studies in different autoimmune diseases.
Another example is the first-in-human RCT of a selective Janus kinase inhibitor type 1 (JAK-1) with single and multiple ascending doses up to 10 days in healthy volunteers. 
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